Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1590/S1806-37562016042020068 http://scihub22266oqcxt.onion/10.1590/S1806-37562016042020068 C4853069!4853069 !27167437     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27167437 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27167437 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Bras+Pneumol 2016 ; 42 (2 ): 146-54 Nephropedia Template TP {{tp|p=27167437 |t=2016. New anticoagulants for the treatment of venous thromboembolism |pdf=|usr=}}{{27167437 }} gab.com Text New anticoagulants for the treatment of venous thromboembolism JO: J Bras Pneumol http://www.kidney.de/pget.php?&tw=1&pmid=27167437 #FOAvip Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum of VTE presentations ranges, by degree of severity, from deep vein thrombosis to acute pulmonary thromboembolism. Treatment is based on full anticoagulation of the patients. For many decades, it has been known that anticoagulation directly affects the mortality associated with VTE. Until the beginning of this century, anticoagulant therapy was based on the use of unfractionated or low-molecular-weight heparin and vitamin K antagonists, warfarin in particular. Over the past decades, new classes of anticoagulants have been developed, such as factor Xa inhibitors and direct thrombin inhibitors, which significantly changed the therapeutic arsenal against VTE, due to their efficacy and safety when compared with the conventional treatment. The focus of this review was on evaluating the role of these new anticoagulants in this clinical context. Twit Text FOAVip New anticoagulants for the treatment of venous thromboembolism ????J Bras Pneumol http://www.kidney.de/pget.php?&tw=1&pmid=27167437 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27167437 #FOAvip English Wikipedia <ref>{{Cite pmid|27167437 }}</ref> New anticoagulants for the treatment of venous thromboembolism #MMPMID27167437 Fernandes CJ ; Alves Júnior JL ; Gavilanes F ; Prada LF ; Morinaga LK ; Souza R J Bras Pneumol 2016[Apr]; 42 (2 ): 146-54 PMID27167437 show ga Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum of VTE presentations ranges, by degree of severity, from deep vein thrombosis to acute pulmonary thromboembolism. Treatment is based on full anticoagulation of the patients. For many decades, it has been known that anticoagulation directly affects the mortality associated with VTE. Until the beginning of this century, anticoagulant therapy was based on the use of unfractionated or low-molecular-weight heparin and vitamin K antagonists, warfarin in particular. Over the past decades, new classes of anticoagulants have been developed, such as factor Xa inhibitors and direct thrombin inhibitors, which significantly changed the therapeutic arsenal against VTE, due to their efficacy and safety when compared with the conventional treatment. The focus of this review was on evaluating the role of these new anticoagulants in this clinical context. |Anticoagulants/*therapeutic use [MESH] |Dabigatran/therapeutic use [MESH] |Humans [MESH] |Pyrazoles/therapeutic use [MESH] |Pyridines/therapeutic use [MESH] |Pyridones/therapeutic use [MESH] |Rivaroxaban/therapeutic use [MESH] |Thiazoles/therapeutic use [MESH] |Time Factors [MESH] |Venous Thromboembolism/*drug therapy [MESH]New anticoagulants for the treatment of venous thromboembolism (epmc).pdf DeepDyve Pubget Overpricing